The IPO of Hexagon Nutrition opened on 5 June 2026 at a price range of ₹42–₹45 per share and raised ₹41.66 crore from anchor investors. On Day 1, the IPO was subscribed 0.36 times and the grey market premium (GMP) was around ₹10–₹12, which means a potential 22–26% listing gain.
Key IPO Details
Issue size: ₹138.87–₹139 crore (entirely Offer for Sale of 3.08 crore shares).
Price Band: ₹42–₹45 per equity share.
Lot size: 333 shares per lot (₹14,985 minimum investment for retail).
Anchor Investment: ₹41.66 crore raised; Bandhan Small Cap Fund and Ampersand Growth Opportunities Fund among the key participants.
Registrar: Kfin Technologies Ltd.
Listing: Proposed on both BSE and NSE.
Timeline:
Open: June 5, 2026
Close: June 9, 2026
Allotment: June 10, 2026
Listing: June 12, 2026Day 1 Subscription Status. Overall Subscription: 0.28–0.36 times.
Retail Investors: 0.45–0.59 times.
Non-Institutional Investors (NII): 0.24–0.30 times.
Qualified Institutional Buyers (QIBs): Yet to show interest (0.0 times).
Grey Market Premium (GMP). GMP Today: ₹10–₹12.
Estimated Listing Price: Around ₹55–₹57.
Potential Gain: 22–26% over the upper price band.
As always, GMP is speculative and unofficial, but it indicates positive sentiment.
About Hexagon Nutrition
Hexagon Nutrition started as a micronutrient formulation company in 1993. Now offers clinical nutrition, therapeutic products, wellness supplements, and fortified foods. Pentasure, Obesigo, and Pediagold are the major brands. With a big portfolio of health and wellness, presence in 75 countries, a strong portfolio in health and wellness.
Expert Review
Brokerage reports indicate that at the upper price band, the IPO is valued at a P/E of ~25.7x (FY25 earnings). Hexagon Nutrition’s leadership in the nutrition segment, integrated business model, and strong brand portfolio are reasons to subscribe for medium to long-term growth. Risks & Considerations
Low Day 1 subscription indicates cautious investor sentiment.
Entirely an Offer for Sale (OFS), meaning no fresh capital infusion into the company.
GMP is speculative and may not reflect actual listing performance.
